Background
==========

Asthma, atopic dermatitis (AD) and chronic obstructive pulmonary disease (COPD) are common chronic inflammatory diseases with prevalence rates between 5 and 15%, making them major public-health problems worldwide \[[@B1],[@B2]\]. For all three diseases, a multifactorial background has been suggested with genetic as well as environmental factors influencing disease susceptibility \[[@B3]-[@B5]\]. There is now strong evidence that exposure to microbial products in early childhood plays an important role in the postnatal maturation of the immune system and that the increase in the prevalence of allergic diseases over the last few decades might be in part due to the decreased microbial burden in industrialized countries (the so-called hygiene hypothesis) \[[@B6],[@B7]\]. The receptor system that constitutes the first, innate immune response to microbial stimuli consists of the family of toll-like receptors (TLRs), highly conserved receptor complexes that recognize pathogen-associated molecular patterns (PAMPs) \[[@B8]\]. Currently, 10 different TLRs are known each of which recognizes a different spectrum of PAMPs. As activators of cytokine production in response to infections, TLRs are believed to be involved in the establishment of T helper (Th)1 immune responses in early life, counter-balancing the Th2-dominated cytokine spectrum at birth \[[@B9]\]. Genetic variation in these receptors could thus influence susceptibility for both Th1- (*e.g*., autoimmune) and Th2-mediated (*e.g*., allergic) diseases \[[@B9]\].

While several studies have evaluated the role of variation in *TLR4*, the receptor for endotoxin, for allergic diseases \[[@B10]-[@B12]\], little is known about the role of *TLR6*variation so far. TLR6 forms heterodimers with TLR2 for recognition of bacterial lipopeptides \[[@B13]\]. Expression of TLR6 has been demonstrated in human mast cells \[[@B14]\] which play an important role in allergic diseases \[[@B15]\]. Interestingly, activation of mast cells *via*, both, TLR4 and TLR2/TLR6 resulted in additive effects on cytokine production \[[@B16]\]. Thus, *TLR6*appears as interesting candidate gene for allergic disorders. The *TLR6*gene is located on chromosome 4p13 and it comprises a single exon encoding a 796 amino-acid polypeptide. Recently, a common coding polymorphism was identified in this gene that leads to an exchange from serine to proline at position 249 in the extracellular domain of the TLR6 protein \[[@B17]\]. In preliminary analyses, the T allele (249Ser) was associated with protection from asthma in African American samples, while the same trend was not significant for European Americans \[[@B17]\]. Although the association reported in this study is intriguing considering the hygiene hypothesis, a replication of this finding for asthma in a different sample has not yet been accomplished. We further speculated that *TLR6*coding variation might also play a role in the pathogenesis of COPD since it is -- like asthma -- a common chronic lung disease characterized by chronic airway inflammation and airway hyper-responsiveness \[[@B1]\]. In addition, there is growing evidence that at least part of the genetic background might be common among COPD and asthma \[[@B18]\]. We therefore studied the *TLR6*Ser249Pro polymorphism in four different German cohorts: adult asthmatics, pediatric asthmatics, patients with COPD and patients with AD in comparison with matched German controls.

Methods
=======

Subjects
--------

185 unrelated adult patients with COPD and 68 unrelated adult patients with asthma were recruited while hospitalized at the Bergmannsheil clinics, Ruhr-University Bochum, Germany, and 132 unrelated children with asthma in the Pediatric Pneumology Studycenter (PPS) located at the same place. The COPD diagnosis was based on the classification of the Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria \[[@B19]\]. Patients included in the study had at least a forced expiratory volume in one second (FEV~1~) of \< 80% of predicted and a FEV~1~/FVC (forced vital capacity) ratio of \< 70% of predicted, classified as moderate to severe COPD (GOLD stages II-IV). Adult asthmatics had a doctor\'s diagnosis of asthma according to the standards of the American Thoracic Society \[[@B20]\]. The exclusion criteria were α1-antitrypsin deficiency, dyspnea of other origin (including cardiovascular disorders, pneumonia, interstitial lung disease, pleural disease, upper airways obstruction, neuromuscular disease and anaemia) and bronchial carcinoma. For the asthmatic children, the asthma diagnosis was based on the ISAAC questionnaire \[[@B21]\]. Disease severity was assessed by a symptom score recently validated \[[@B22]\]. 294 unrelated patients with AD were recruited by a consultant specialist for AD (QP, Gladbeck, Germany), including 175 children and 119 adults. The AD diagnosis was based on the presence of clinical features, including purities, eczema with age-dependent differences in location, xerosis and chronic or relapsing dermatitis. In addition, all investigated AD patients had a positive family history for atopic diseases.

212 control samples from adults without known allergies, asthma or AD were collected in the same private practice as the AD patients. We specifically chose to use non-allergic adults as controls because for diseases as frequent as asthma and AD, the risk remains very high for asymptomatic children to develop an allergic disease during childhood or even adulthood \[[@B23],[@B24]\]. The control subjects underwent clinical examination in order to exclude symptoms of asthma, AD or COPD, had no self-reported allergies or allergic symptoms and no first degree relatives with known allergic diseases. Lung function tests or IgE measures were not performed for the controls. All patient and control subjects were Caucasians of German origin. Informed consent was obtained from all subjects. The study was approved by the Ethics Committee of the University of Bochum and the Declaration of Helsiniki protocols were followed. DNA was extracted from EDTA anti-coagulated peripheral blood by using a standard salting-out method \[[@B25]\].

Genotyping
----------

Genotyping of the *TLR6*Ser249Pro polymorphism was performed by polymerase chain reaction (PCR) with subsequent restriction enzyme digestion. PCR reactions were performed in a total volume of 10 μl, containing 50 ng DNA, 200 mmol of each dNTP, 3 mmol MgCl~2~, 10 pmol of each primer (forward: GCATTTCCAAGTCGTTTCTATGT; reverse: GCAAAAACCCTTCACCTTGTT), and 0.4 U Taq polymerase (Genecraft, Münster, Germany). Thermal cycling was performed (Biometra, Göttingen, Germany). After two initial cycles at 6°C and 3°C above the annealing temperature, 27 cycles of 95°C (30 sec), 57°C (60 sec) and 72°C (60 sec) were run. The PCR product was digested with Ava II (0.01 U/ng DNA) at 37°C for three hours. The fragments were subsequently separated on 2% agarose gels in 1 × TBE buffer (30 min, 200 V) and visualized using ethidium bromide staining.

Statistical analyses
--------------------

Genotype and allele frequencies were ascertained by direct counting and subsequently analyzed according to the χ^2^method. Deviations from Hardy-Weinberg equilibrium were evaluated using the FINETTI program. P \< 0.05 was considered to be significant. Power calculations were performed using the *Power and sample size program*\[[@B26]\].

Results and discussion
======================

Clinical data concerning the four patient groups are summarized in table [1](#T1){ref-type="table"}. Since the nucleotide substitution from C to T at position 744 in the *TLR6*gene results in the creation of a new restriction site, the Ser249Pro polymorphism was genotyped by restriction enzyme digestion. Genotype frequencies for case and control groups are shown in table [2](#T2){ref-type="table"}. The frequencies in all five groups were in Hardy-Weinberg equilibrium. There was a significant association between the T allele (249Ser) and childhood asthma (p = 0.03, table [3](#T3){ref-type="table"}). Yet, significance was lost after Bonferroni correction. For the other three case groups, no significant association was observed.

Although it seems puzzling to identify the opposite allele being associated with childhood asthma as compared to the one reported by Tantisira et al. \[[@B17]\], there are plausible explanations for this phenomenon. First, the association with childhood asthma reported here is only a weak association that did not withstand Bonferroni correction. Yet, we consider the study to be explorative and hypothesis-generating and find the results intriguing in the light of the emerging role of TLRs in allergic diseases \[[@B9]\]. In addition, the reported association refers to a coding variation that might at least theoretically have functional consequences. It remains largely unknown what sort of genetic variants explain inherited variation in complex traits, but recent evidence suggests that common, non-coding genetic variants will explain at least some of the inherited variation in susceptibility to common disease \[[@B27]\]. Thus, testing a single functional variation would be more likely biased into the direction of a negative result rather than of a positive association.

Second, the previous association of the 249Ser allele with protection from asthma was defined in a sample of African American patients and controls. The minor allele frequency of the Ser249Pro polymorphism in this cohort was 0.08 in asthmatics and 0.19 in controls \[[@B17]\] and thus much lower than in our four German cohorts with a minor allele frequency of on average 0.40 (range 0.35 to 0.49). Yet, the allele frequencies we observed in this study are comparable to the ones for European Americans \[[@B28]\]. It appears possible that the Ser249Pro polymorphism might not be disease-causing by itself, but instead be in linkage disequilibrium with the true disease-causing variation. In this case, different alleles of Ser249Pro could be linked to the relevant allele in different populations (*e.g*., African Americans and Caucasians). Further association studies in these and other populations are needed to answer this question.

Third, environmental factors might play a role in disease susceptibility associated with opposite alleles. One such example has been described for CD14, which associates with TLR4 to form the receptor complex that recognizes lipopolysaccharide (LPS, endotoxin). A single nucleotide polymorphism (SNP) in the *CD14*promoter at position -159 (C/T) was identified \[[@B29]\]. The -159T allele was associated with high levels of soluble CD14 and decreased total serum IgE in a cohort of children from Tucson, Arizona \[[@B29]\]. Yet, no association of this SNP with allergy or IgE levels was evident in a large German cohort \[[@B30]\]. In the Hutterites, an isolated population from South Dakota, the -159T allele was instead associated with increased risk for atopy \[[@B31]\]. Vercelli recently postulated an intriguing explanation for this phenomenon: she suggested that the level of endotoxin exposure influences the \'switch\' from the Th2-biased cytokine profile at birth to a Th1-biased cytokine profile in early childhood, and that endotoxin levels might interact with the *CD14*genotype to confer either risk to or protection from atopic phenotypes later in life \[[@B32]\]. Thus, environmental factors -- and even endotoxin load -- might also be responsible for the discrepancy between the findings of Tantisira et al. \[[@B17]\] and our results, concerning the role of the Ser249Pro polymorphism in asthma pathogenesis. Since we did not yet measure endotoxin levels, we are unable to explore this question at the moment.

Association studies of polymorphisms in other *TLR*genes have also revealed somewhat contradictory results. Two missense mutations (Asp299Gly and Thr399Ile) in the gene encoding TLR4 which mediates the biological response to LPS were associated with a decreased response to inhaled endotoxin in humans \[[@B33]\]. Since exposure to LPS in early life has been suggested to exert protective effects on the development of allergic diseases \[[@B34]-[@B36]\], the *TLR4*gene appeared to be an outstanding functional candidate for the susceptibility to asthma and allergic diseases. Yet only one out of four association studies found a direct association of the *TLR4*Asp299Gly polymorphism with asthma \[[@B10]\]. In three other studies, no differences in the overall risk for asthma between carriers of the wild type and mutant genotypes were obvious \[[@B11],[@B12],[@B37]\]. On the other hand, an impact of this polymorphism on the severity of atopy in asthmatics \[[@B11]\] was reported as well as a modified response to endotoxin \[[@B12]\], indicating gene/environment interplay. Similarly, a polymorphism at position -16934 in the *TLR2*gene was significantly associated with asthma and atopy in farmers\' children but not in children that did not grow up on farms \[[@B38]\], pointing again to a gene/environment interaction. Thus, variation in *TLR*genes appears to have modifying effects on asthma susceptibility.

The fact that we did not find an association of the Ser249Pro polymorphism with adult asthma might be due to the small sample size of adult asthmatics. Yet, in order to achieve a significance level of 0.05 with a statistical power of 80%, a sample size of over 500 patients would have been required. Replication studies in larger cohorts as well as functional studies are clearly needed. To our knowledge, this is the first evaluation of the *TLR6*Ser249Pro polymorphism in patients with atopic dermatitis, and we did not find association with this allergic skin disease, suggesting that the observed association might be restricted to (childhood) asthma, rather than allergic diseases in general. This finding is not totally unexpected since the results of genome-wide screens indicate that loci linked to AD do not overlap substantially with loci linked to asthma and related phenotypes, but rather with loci for psoriasis, another chronic skin disease \[[@B4]\]. Furthermore, we did not find evidence that *TLR6*Ser249Pro contributes to susceptibility for COPD.

Conclusion
==========

We found a weak association between the *TLR6*Ser249Pro polymorphism and risk for childhood asthma, while no association was evident for AD or COPD. Analysis of the effect of this variation on disease severity and potential gene/environment interactions might be a promising approach since gene/environment interactions have been described for other *TLR*genes. Further studies of the *TLR6*Ser249Pro polymorphism in ethnically well-defined cohorts as well as functional studies of this variation are warranted to evaluate its role in the pathogenesis of allergic diseases.
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###### 

Clinical data of the asthma, AD and COPD cohorts as well as the control group

                                  Adult patients with asthma   Children with asthma   AD             COPD          Healthy controls
  ------------------------------- ---------------------------- ---------------------- -------------- ------------- ------------------
  number of subjects              68                           132                    294            182           212
  gender: f/m                     36/32                        52/80                  180/114        62/120        131/81
  age (years) \[median(range)\]   38 (18--68)                  9.5 (2--15)            12 (0.5--72)   68 (33--81)   59 (22--87)
  FEV1 (%pred.) (mean ± STD)      73 ± 25                      97 ± 18                \--            47 ± 19       \--
  FEV1/FVC ratio (mean ± STD)     65 ± 16                      98 ± 15                \--            49 ± 15       \--
  pack years \[median(range)\]    2 (0--44)                    \--                    \--            30 (0--200)   \--

###### 

Genotype frequencies of the *TLR6*Ser249Pro polymorphism in the case and control groups.

  *TLR6*Ser249Pro   Controls   Asthma adults   Asthma children   AD        COPD
  ----------------- ---------- --------------- ----------------- --------- ---------
                    N = 212    N = 68          N = 132           N = 294   N = 185
                                                                           
  Pro/Pro           75         28              32                108       76
  Pro/Ser           104        32              72                138       80
  Ser/Ser           33         8               28                48        29
                                                                           
  p-value           \-         n.s.            0.07              n.s.      n.s.

###### 

Allele frequencies of the *TLR6*Ser249Pro polymorphism in asthma children *vs*. controls.

  --------------------------------------
        Asthma children\   Controls\
        N = 132            N = 212
  ----- ------------------ -------------
  Pro   136 (51.5%)        254 (59.9%)

  Ser   128 (48.5%)        170 (40.1%)

        p = 0.03           
  --------------------------------------
